Global Pediatric Drugs Market Poised for Rapid Growth, Predicted to Reach $287.6 Billion by 2033

News provided by

Nov 01, 2023, 18:30 ET

DUBLIN, Nov. 1, 2023 /PRNewswire/ -- The "Pediatric Drugs Market by Type, by Route of Administration, Distribution Channel, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

The global pediatric drugs market is experiencing significant growth and is expected to continue expanding at a Compound Annual Growth Rate (CAGR) of 8.42% during the forecast period from 2023 to 2033. In 2022, the market size reached USD 118.20 billion, and it is projected to reach USD 287.6 billion by 2033.

Several key factors are driving this growth:

Rising Incidence of Pediatric Diseases: The increasing prevalence of pediatric illnesses, including respiratory disorders, autoimmune disorders, and rare pediatric diseases, is driving the demand for specialized medications tailored to address these health issues in children.
Advances in Pediatric Research: Ongoing advances in pediatric research are leading to the development of innovative medications and therapies for children, improving treatment options for pediatric patients.
Focus on Rare Pediatric Diseases: Pharmaceutical companies are increasingly focusing on rare pediatric diseases, leading to the development of drugs specifically designed to treat these conditions.
Parental Awareness and Advocacy: Parental awareness and advocacy for pediatric healthcare needs are contributing to increased demand for pediatric medications and treatments.
Technological Advancements: Technological advancements are enhancing the diagnosis and treatment of pediatric diseases, further fueling market growth.

Despite the positive outlook, several challenges may limit market growth:

Lack of Pediatric-Specific Data: Limited availability of pediatric-specific data and clinical trials can hinder drug development for children.
Ethical and Regulatory Constraints: Ethical considerations related to pediatric clinical trials and regulatory constraints can slow down the development and approval of pediatric drugs.
Rapid Growth and Change: The rapid growth and change in the field of pediatric medicine require pharmaceutical companies to adapt quickly to evolving healthcare needs and regulatory requirements.

Market Segmentation:

The pediatric drugs market is segmented based on various factors:

Type: Segments include respiratory disorder drugs, autoimmune disorder drugs, rare pediatric disease drugs, and others. Respiratory disorder drugs currently account for the highest revenue share.
Route of Administration: Segments include oral medications, topical medications, and others. Oral medications are the preferred route for pediatric drug delivery.
Distribution Channel: Segments include hospital pharmacies, online pharmacies, and others. Hospital pharmacies currently hold the highest revenue share.

Regional Markets:

North America: The region held the top spot in terms of revenue in 2022 due to its well-established healthcare infrastructure, high healthcare expenditure, advanced research and development capabilities, and robust regulatory framework.
Asia Pacific: This region is expected to grow at the fastest CAGR during the forecast period due to its rapidly expanding pediatric population, increased healthcare spending, improved healthcare infrastructure, and growing awareness of pediatric healthcare.

Competitor Insights:

Key players in the pediatric drugs market include Pfizer Inc., Novartis AG, Johnson & Johnson, GlaxoSmithKline plc, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Merck & Co., Inc., Roche Holding AG, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, and Bayer AG.

These organizations employ various growth strategies, including strategic alliances, partnerships, and agreements with other companies, to outperform their competitors and drive market expansion. For example, companies like Eli Lilly and Company and Merck & Co. have submitted new drug applications and received approvals for pediatric treatments, further expanding their product portfolios in the pediatric drugs market.

For more information about this report visit https://www.researchandmarkets.com/r/uslqv9

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets